Kansas City Research Institute | Kansas City, MO
Status and phase
Conditions
Treatments
About
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subjects must meet the following criteria to be eligible for study participation:
Exclusion criteria
Subjects must not meet any of the following criteria to be eligible for study participation:
Primary purpose
Allocation
Interventional model
Masking
150 participants in 2 patient groups
Loading...
Central trial contact
Barry Crittenden, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal